Medication Nonadherence in Diabetes

Abstract

OBJECTIVETo examine the longitudinal effects of medication nonadherence (MNA) on key costs and estimate potential savings from increased adherence using a novel methodology that accounts for shared correlation among cost categories.RESEARCH DESIGN AND METHODSVeterans with type 2 diabetes (740,195) were followed from January 2002 until death, loss to follow-up, or December 2006. A novel multivariate, generalized, linear, mixed modeling approach was used to assess the differential effect of MNA, defined as medication possession ratio (MPR) ≥0.8 on healthcare costs. A sensitivity analysis was performed to assess potential cost savings at different MNA levels using the Consumer Price Index to adjust estimates to 2012 dollar value.RESULTSMean MPR for the full sample over 5 years was 0.78, with a mean of 0.93 for the adherent group and 0.58 for the MNA group. In fully adjusted models, all annual cost categories increased ∼3% per year (P = 0.001) during the 5-year study time period. MNA was associated with a 37% lower pharmacy cost, 7% lower outpatient cost, and 41% higher inpatient cost. Based on sensitivity analyses, improving adherence in the MNA group would result in annual estimated cost savings ranging from ∼$661 million (MPR <0.6 vs. ≥0.6) to ∼$1.16 billion (MPR <1 vs. 1). Maximal incremental annual savings would occur by raising MPR from <0.8 to ≥0.8 ($204,530,778) among MNA subjects.CONCLUSIONSAggressive strategies and policies are needed to achieve optimal medication adherence in diabetes. Such approaches may further the so-called “triple aim” of achieving better health, better quality care, and lower cost.

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

“…Qualitatively similar results have been shown in Europe (9). In addition to the negative impact on achieving effective glycemic control, poor medication adherence results in increased health care costs (1,2). Therefore, it stands to reason that in order to reduce the overall burden of diabetes, it is critical to address the issues of poor medication adherence.…”

“…Although numerous drugs are available for individualized management of type 2 diabetes, poor treatment adherence, suboptimal efficacy, inadequate weight control, and unacceptable tolerability remain barriers to glycemic control (1)(2)(3). Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) are considered effective therapeutic agents for the treatment of type 2 diabetes (4) that lower glucose, promote weight loss, and have a low risk of hypoglycemia (5) due to their glucose-dependent effect on insulin secretion (6).…”

Geographic and Racial/Ethnic Variations in Patterns of Multimorbidity Burden in Patients with Type 2 Diabetes

“…21 22 We also considered medication status (receipt versus non-receipt of prescription for diabetes medication during the study period) and service-connected disability as a dichotomous (<50%, ≥50%) proxy variable to measure copay status, as has been done in multiple prior studies. 17,[23][24][25] Outcome measure…”

Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study

“…Despite a wide choice of pharmacological interventions, many patients do not achieve adequate control of hyperglycemia (1). Poor compliance with complex medical regimens (2) and the fact that most available pharmaceutical approaches do not adequately address underlying pathophysiological defects may explain the limited efficacy of current therapies.…”